More Evidence For Left Main PCI

Courtesy of Dr. Carlos Fava.

left main PCILeft main coronary artery disease (LMD), has historically been treated with myocardial revascularization surgery (CABG), but for some years now, and with the development of new drug eluting stents (DES), percutaneous coronary intervention (PCI) has been gathering support in this challenging territory.

 

The study analyzed the SYNTAX and PRECOMBAT populations presenting severe left main disease.

 

It included 1,305 patients (657 treated with PCI and 648 with CABG) and MACE were analyzed at 5 years.

 

Mean population age was 64, most of patients were men and 28% were diabetic. Baseline characteristics were well balanced between populations.

 

At 5 years, MACE was 28.3% for the PCI group and 23% for the CABG group (HR: 1.23; CI 95% 1.01 to 1.55; p=0.045). This difference was mainly driven by the higher rate of repeat revascularization associated to PCI (19.5% vs. 10.8%; HR: 1.85; CI 95% 1.38 to 2.47; p<0.001). Both strategies showed similar death and infarction rates, but there was higher stroke rate in favor of PCI.

 

In patients presenting only LMD or LM + one vessel disease, PCI was associated to a 60% reduction in all-cause mortality. (HR: 0.40; CI 95% 0.20 to 0.83; p=0.029) and a 67% reduction in cardiac mortality (HR: 0.33; CI 95% 0.12 to 0.88; p=0.025) compared to CABG.

 

Conclusion

In patients with left main disease, myocardial revascularization surgery and PCI present similar rates of death, MI and stroke. In the LMD group or LM + 1 vessel disease, PCI was associated to lower all-cause and cardiac death.

 

Editorial Comment

This analyzis of two large randomized studies with the first two DES, shows promising results, especially in patients with low or intermediate anatomical risk, with lower cardiac and non-cardiac mortality, but with higher reintervention rate.

 

Courtesy of Dr. Carlos Fava. Favaloro Foundation, Buenos Aires, Argentina.

 

Original Title: Outcomes After Percutaneous Coronary Intervention or Bypass Surgery in Patients with Unprotected Left Main Disease

Reference: Rafael Cavalcante et al. J Am Cardiol 2016;68:999-1009.


Suscríbase a nuestro newsletter semanal

Reciba resúmenes con los últimos artículos científicos

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization. There are several tools currently used to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...